ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

Clinical and Experimental Immunology, published by Oxford University Press, is a premier journal that has been a cornerstone in the field of immunology since its inception in 1966. With an ISSN of 0009-9104 and an E-ISSN of 1365-2249, this journal holds a significant position in academic research, currently ranking in the Q2 category for both Immunology and Allergy (2023). Its impactful contributions are reflected in its Scopus rankings, where it stands at Rank #63 out of 233 in Immunology and Allergy, placing it in the 73rd percentile, and Rank #73 out of 236 in Immunology and Microbiology. Researchers, healthcare professionals, and students will find this journal an invaluable resource for cutting-edge studies, reviews, and clinical advancements in the ever-evolving domain of immunology. While the publication does not offer open-access options, it remains a pivotal platform for disseminating knowledge that impacts both clinical practice and experimental research.

Mucosal Immunology, published by Elsevier Science Inc, is a leading journal dedicated to advancing the field of immunology with a particular focus on mucosal immunity. Since its inception in 2008, the journal has established itself as a premier source of cutting-edge research, evidenced by its impressive Q1 ranking in both Immunology and Allergy for 2023, and its notable positions within the top ranks of Scopus (Rank #21/233 in Immunology and Allergy and Rank #24/236 in Immunology and Microbiology). The journal serves as a vital resource for researchers, professionals, and students aiming to explore the complexities of mucosal immune responses and their implications in health and disease. While it operates under a subscription model, Mucosal Immunology is committed to disseminating quality research globally and enhancing collaborative efforts within the scientific community. Explore the latest findings and connect with influential scholarship in this rapidly evolving field.

INFECTION AND IMMUNITY is a distinguished peer-reviewed journal published by the American Society for Microbiology, focusing on groundbreaking research in the fields of infection, immunology, microbiology, and parasitology. Established in 1971, this journal has built a robust legacy, converging years of scientific discovery with a vision towards 2024 and beyond. With an impressive Impact Factor, the journal holds significant rankings in various categories; its Q1 status in both Infectious Diseases and Parasitology underscores its high relevance and quality within the scientific community. Researchers and professionals alike will benefit from its content, as it promotes the latest advances in understanding immune responses and infectious agents, further legitimizing its place among the top quartiles of its respective fields. Access options are provided through traditional subscription models, ensuring a broad charitable dissemination of knowledge. As a pivotal resource for scholars and practitioners alike, INFECTION AND IMMUNITY stands at the forefront of microbiological and immunological research, fostering essential discourse that is crucial for advancing public health and scientific insight.

CRITICAL REVIEWS IN IMMUNOLOGY, published by BEGELL HOUSE INC, is an essential journal in the field of immunology that has been contributing to the scientific discourse since 1980. With its ISSN 1040-8401 and E-ISSN 2162-6472, this journal provides a platform for critical analysis and comprehensive reviews that deepen understanding of immune responses and their implications in health and disease. Although currently categorized in the Q4 quartile for Immunology and Q3 for Immunology and Allergy, the journal's quality research and scholarly contributions are crucial for advancing knowledge within its fields—encompassing various aspects of innate and adaptive immunity. Researchers and professionals in immunology will find invaluable insights, aiding them in their quest for innovation and excellence, as the journal aims to foster interdisciplinary collaboration. While it does not operate on an open-access model, CRITICAL REVIEWS IN IMMUNOLOGY remains a significant resource for those dedicated to pushing the boundaries of immunology, with annual publications expected to last well into 2024 and beyond.

Immunity, Inflammation and Disease is a premier open-access journal published by WILEY, dedicated to advancing the field of immunology and allergy. Launched in 2013, this journal has established itself as a significant platform for researchers and professionals to disseminate high-quality research findings and innovative insights that address critical issues in immune responses and inflammatory diseases. With an impact factor that reflects its growing influence and a current ranking in Q3 for Immunology and Q2 for Immunology and Allergy, this journal serves a diverse audience keen on exploring cutting-edge developments. Researchers are encouraged to submit their work to share their findings with a global reach, foster collaboration, and enhance the understanding of immune mechanisms and therapeutic strategies. Accessible since its inception, Immunity, Inflammation and Disease is committed to open science, ensuring that vital research is freely available for the advancement of knowledge within the academic community and beyond.

CELLULAR IMMUNOLOGY is a prestigious journal published by Academic Press Inc. Elsevier Science, dedicated to advancing the field of immunology. Established in 1970 and converging ongoing research up to 2024, this journal has carved out a significant niche within the academic community, boasting a notable Q2 ranking in the Immunology category and holding a respectable 67th percentile ranking within Scopus for its contributions to the disciplines of Immunology and Microbiology. The journal serves as a vital platform for disseminating high-quality research, reviews, and methodologies that elucidate the intricacies of cellular immune responses, thereby benefiting researchers, professionals, and students alike. Although it does not offer open access, the journal's impact is evidenced by its comprehensive coverage of pioneering studies and ongoing developments in the immunological sciences, positioning it as an essential resource for those seeking to deepen their understanding and engage with the latest findings in cellular immunology.

Immunotherapy Advances, published by Oxford University Press, stands at the forefront of the rapidly evolving field of immunology and microbe interactions, focusing specifically on novel immunotherapeutic strategies and their clinical applications. Established in 2021, this peer-reviewed journal aims to disseminate high-quality research that contributes to the understanding and advancement of immunotherapeutic techniques, potentially transforming patient care in immunology. With a current Scopus rank of #140 out of 236 in the realm of Immunology, placing it in the 40th percentile, Immunotherapy Advances is positioned to be an integral resource for researchers, healthcare professionals, and students eager to stay updated with groundbreaking findings and methodologies. The journal is dedicated to fostering innovative discussions and collaborations, ensuring open access to vital research that influences treatment paradigms globally.

Immunity is a premier journal published by CELL PRESS that has positioned itself at the forefront of immunological research since its inception in 1994. With its ISSN 1074-7613 and E-ISSN 1097-4180, this prestigious journal is recognized for its significant contribution to the fields of Immunology, Allergy, and Infectious Diseases, consistently achieving a Q1 ranking in these categories as per 2023 metrics. The journal is highly esteemed within the academic community, holding impressive Scopus rankings—4th out of 344 in Infectious Diseases and 3rd in both Immunology and Immunology and Allergy—placing it in the 98th percentile. Although not an Open Access journal, it provides critical insights and research developments that empower researchers, healthcare professionals, and students alike. With a commitment to advancing scientific knowledge, Immunity is crucial for those interested in understanding immune responses and their implications for health and disease.

Seminars in Immunopathology is a premier academic journal published by SPRINGER HEIDELBERG, focusing on the intricate relationships between immune responses and pathologies. With an ISSN of 1863-2297 and an E-ISSN of 1863-2300, this journal delivers cutting-edge research and insights to its readers, contributing significantly to the fields of immunology and allergy, as reflected in its Q1 quartile ranking in both categories for 2023. Positioned in a highly competitive niche, it ranks #18 out of 233 in Immunology and Allergy and #22 out of 236 in Immunology and Microbiology, highlighting its impact within the scientific community. Seminars in Immunopathology publishes comprehensive reviews and research articles, aiming to advance understanding of immune mechanisms in disease and promote interdisciplinary collaboration. Accessible from Germany, this journal is a vital resource for researchers, clinicians, and students seeking to stay at the forefront of immunological advancements and therapeutic innovations.